Latest goodwill for TARO: $17M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2024), TARO shows a goodwill of $17M. That compares with $17M in the prior-year period — up 0.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, TARO's goodwill is now $17M (was $17M) — essentially flat versus a year earlier. Pairing that YoY change with peer averages gives a clearer picture of whether Taro Pharmaceutical Industries is outperforming or lagging.
Tracking TARO's goodwill over time shows whether Taro Pharmaceutical Industries is scaling, shrinking, or reshaping that part of the business. The current reading is $17M That compares with $17M in the prior-year period — up 0.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this goodwill page, Stockcircle has Taro Pharmaceutical Industries's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect goodwill (currently $17M) with ownership activity and broader fundamentals.
Taro Pharmaceutical Industries's goodwill is $17M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.